SRNE News and Press, Sorrento Therapeutics Inc. From 11/01/21

Sorrento Therapeutics (NASDAQ:SRNE) license partner China Oncology Focus has submitted a new drug application for socazolimab for the greater China territory to treat recurrent or metastatic cervical cancer. China Oncology Focus is an affiliate of Lee's Pharmaceutical Holdings....

Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lee’s Pharma. China National Medical Products Administration (NMPA) accepted the filing of socazolimab for the cervical cancer indication. SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSW...

Abivertinib is an oral capsule (100 mg QD or two 50-mg capsules a day) that potentially reduces cytokine storm associated with acute respiratory distress syndrome (ARDS) in severe hospitalized COVID-19 patients. Preliminary results from two completed Phase 2 studies: US study (N=96) a...

Abivertinib is an oral capsule (100 mg QD or two 50-mg capsules a day) that potentially reduces cytokine storm associated with acute respiratory distress syndrome (ARDS) in severe hospitalized COVID-19 patients. Preliminary results from two completed Phase 2 studies: US study (N=96) a...

COVISTIX has received CE mark and marketing authorization from FAMHP (Federal Agency for Medicines and Health Products) that enables Sorrento to sell this device in all territories that accept the Qarad EC-Rep (Belgium) CE Mark for commercialization. Distribution contracts are being n...

Palm Beach, FL – October 20, 2021 – FinancialNewsMedia.com News Commentary – Recently, scientific reports have shown that a universal coronavirus vaccine that protects against COVID-19 causing SARS-CoV-2, as well as other coronaviruses such as those causing ...

Anti-TROP-2 ADC with a drug payload SN38 (a DNA polymerase inhibitor) (ESG-401) has received FDA authorization to begin clinical trials in the US. ESG-401 addresses a highly unmet need for the treatment of multiple solid tumors, including triple-negative breast cancer and urotheli...

Phase 2 trial of resiniferatoxin (RTX) to proceed following clearance from FDA. The decision is supported by the Phase 1 data confirming RTX safety for epidural administration without dose limiting toxicity at any doses tested up to 30 ug. Safety and initial pain relief observed i...

First, a striking point about Sorrento Therapeutics is that despite its $1.93 billion market cap, it possesses a wide pipeline, similar to the biggest biopharmaceuticals. Second, it is also generating revenues mainly from a prescription drug and has been able to get EUA approval for C...

Alexandria Real Estate Equities and Kilroy Realty have each made attractive moves to expand their life science portfolios. Recent transactions in the net lease sector by Four Corners Property Trust, CTO Realty, and Realty Income reflect stable cap rates. Gateway office appears to ...